Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62018TA0059

Case T-59/18: Judgment of the General Court of 22 November 2018 — Endoceutics v EUIPO — Merck (FEMIVIA) (EU trade mark — Opposition proceedings — Application for EU word mark FEMIVIA — Earlier EU word mark FEMIBION INTIMA — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EU) 2017/1001)

OJ C 44, 4.2.2019, p. 46–46 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

4.2.2019   

EN

Official Journal of the European Union

C 44/46


Judgment of the General Court of 22 November 2018 — Endoceutics v EUIPO — Merck (FEMIVIA)

(Case T-59/18) (1)

((EU trade mark - Opposition proceedings - Application for EU word mark FEMIVIA - Earlier EU word mark FEMIBION INTIMA - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001))

(2019/C 44/58)

Language of the case: English

Parties

Applicant: Endoceutics, Inc. (Quebec, Canada) (represented by: M. Wahlin, lawyer)

Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO: Merck KGaA (Darmstadt, Germany)

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 27 November 2017 (Case R 280/2017-2), relating to opposition proceedings between Merck and Endoceutics.

Operative part of the judgment

The Court:

1.

Dismisses the action;

2.

Orders Endoceutics, Inc. to pay the costs.


(1)  OJ C 112, 26.3.2018.


Top